Educational Sessions: 'CDK4/6 for ER+'

preview_player
Показать описание
EDUCATIONAL SESSIONS
Emerging Adjuvant Therapies: What’s Ready for Prime Time?
CDK4/6 for ER+
Ingrid A. Mayer, MD, MSCI
Vanderbilt-Ingram Cancer Center
Nashville, TN
  1. San Antonio Breast Cancer Symposium
Рекомендации по теме
Educational Sessions: 'CDK4/6 0:21:35

Educational Sessions: 'CDK4/6 for ER+'

Education Session: Treatment 1:55:38

Education Session: Treatment Post CDK 4/6 Inhibitors

Expert report on 0:04:50

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancer

HR+ Breast Cancer: 0:03:56

HR+ Breast Cancer: Risk-Stratifying to CDK4/6 Inhibitors

The Truth About 0:27:49

The Truth About CDK4/6 Inhibitors – New Targeted Treatment Protocol for ER Positive Breast Cancers

Emerging evidence on 0:18:07

Emerging evidence on the role of CDK4/6 inhibitors in early BC

Part 2 - 1:06:57

Part 2 - Session 1 - CDK 4/6 Inhibitors in breast cancer: will they have a Large role in future?

mBC: CDK4/6 Inhibitor 0:03:38

mBC: CDK4/6 Inhibitor Patient Selection/Sequencing

MONARCH 3 study: 0:04:54

MONARCH 3 study: CDK4/6 inhibitors in the treatment of metastatic breast cancer

CDK 4/6 inhibition 0:26:40

CDK 4/6 inhibition in early breast cancer By Dr. Ahmed Saadeddin 18-6-2021 (Day1)

Considerations for Treating 0:05:34

Considerations for Treating Patients with CDK4/6 Inhibitors

ELAINE 1: LAS 0:05:47

ELAINE 1: LAS vs fulv in la ER+/HER2- mBC ESR1m + disease progression on AI and CDK4/6i inhibitors

Erika Hamilton, MD, 0:01:12

Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer

CDK 4/6 inhibitors 0:05:56

CDK 4/6 inhibitors for older women with HR-positive breast cancer

Adjuvant CDK4/6 inhibition 0:06:36

Adjuvant CDK4/6 inhibition in early-stage HR-positive breast cancer | Ruth O'Regan

Spotlight Session: 'Three 0:13:17

Spotlight Session: 'Three CDK 4/6 inhibitors, a lot of biomarkers, what does it all mean moving...

Current Clinical Data 0:21:11

Current Clinical Data for CDK 4/6 Inhibitors in Breast Cancer

The benefits of 0:03:35

The benefits of adjuvant CDK4/6 and PARP inhibition in breast cancer

Changing Standards of 1:17:18

Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer

Patient Management of 0:10:47

Patient Management of CDK 4/6 Inhibitors

Education Session: Trends 1:41:26

Education Session: Trends in Adjuvant Endocrine Therapy

Dr. BarbaraPistilli:Current Clinical 0:18:19

Dr. BarbaraPistilli:Current Clinical Evidence in CDK4/6 inhibitors

CDK4/6 inhibitors in 0:08:30

CDK4/6 inhibitors in ER+ metastatic breast cancer during the COVID-19 pandemic

HR+, HER2 , 0:55:49

HR+, HER2 , High Risk EBC A Practical Roadmap for CDK4 6 Inhibition in the Adjuvant Setting